Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Australian Clinical Labs Ltd

Healthcare AU ACL

2.14AUD
-0.01(0.47%)

Last update at 2026-06-24T04:54:00Z

Day Range

2.112.18
LowHigh

52 Week Range

1.832.92
LowHigh

Fundamentals

  • Previous Close 2.15
  • Market Cap408.48M
  • Volume309173
  • P/E Ratio15.64
  • Dividend Yield5.66%
  • EBITDA81.58M
  • Revenue TTM737.49M
  • Revenue Per Share TTM3.97
  • Gross Profit TTM 270.17M
  • Diluted EPS TTM0.14

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Income before tax 48.18M 48.18M 36.37M 36.37M 48.31M
Minority interest -0.39000M -0.39000M -0.31000M -0.31000M -0.14100M
Net income 32.43M 32.43M 23.93M 23.93M 35.90M
Selling general administrative 329.06M 329.06M 312.67M 312.67M 297.39M
Selling and marketing expenses - - 225.47M -225.47500M -
Gross profit 270.86M 270.86M 138.45M 138.45M 566.02M
Reconciled depreciation 136.04M 136.04M 128.43M 128.43M 122.75M
Ebit 68.00M 68.00M 41.22M 41.22M 62.17M
Ebitda 81.36M 81.36M 169.65M 169.65M 184.93M
Depreciation and amortization 13.35M 13.35M 128.43M 128.43M 122.75M
Non operating income net other - - - - -
Operating income 270.86M 270.86M 56.91M 56.91M 56.07M
Other operating expenses 470.41M 470.41M 633.82M 633.82M 640.14M
Interest expense 18.37M 18.37M 17.04M 17.04M 13.87M
Tax provision 15.36M 15.36M 12.12M 12.12M 12.27M
Interest income 0.41M 0.41M 0.50M 0.50M 0.18M
Net interest income -17.95700M -17.95700M -16.53900M -16.53900M -13.68300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 15.36M 15.36M 12.12M 12.12M 12.27M
Total revenue 741.27M 741.27M 689.73M 689.73M 692.10M
Total operating expenses 89.98M 89.98M 81.55M 81.55M 514.05M
Cost of revenue 470.41M 470.41M 551.28M 551.28M 126.08M
Total other income expense net -222.68000M -222.68000M -20.53900M -20.53900M -7.75600M
Discontinued operations - - - - -
Net income from continuing ops 32.82M 32.82M 24.24M 24.24M 36.04M
Net income applicable to common shares 32.43M 32.43M 23.93M 23.93M 35.90M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Total assets 574.84M 574.84M 593.06M 593.06M 578.91M
Intangible assets 6.10M 6.10M 6.26M - 6.49M
Earning assets - - - - -
Other current assets 11.99M 0.68M 8.50M 8.50M 5.32M
Total liab 402.86M 402.86M 415.30M 415.30M 406.24M
Total stockholder equity 171.35M 171.35M 177.53M 177.53M 172.42M
Deferred long term liab - - - - -
Other current liab 87.27M 0.46M 73.57M 73.57M 0.14M
Common stock 780.73M - 791.76M 791.76M 792.14M
Capital stock 775.52M 775.52M 791.76M - 792.14M
Retained earnings 33.75M 166.54M 159.05M 159.05M 155.24M
Other liab - - - - -
Good will 159.11M 159.11M 158.68M 158.68M 158.68M
Other assets 16.97M - 10.74M 0.00000M 8.23M
Cash 21.44M 21.44M 26.14M 26.14M 19.95M
Cash and equivalents 21.44M - 26.14M - 19.95M
Total current liabilities 216.41M 216.41M 207.70M 207.70M 187.93M
Current deferred revenue - - - 3.24M 68.73M
Net debt 268.94M 20.53M 282.76M 282.76M 296.36M
Short term debt 108.60M - 104.71M 104.71M 101.08M
Short long term debt - - - - -
Short long term debt total 290.38M - 308.90M 308.90M 316.32M
Other stockholder equity -5.20800M - 0.05M - 0.07M
Property plant equipment 270.11M - 281.70M - 288.44M
Total current assets 120.06M 120.06M 133.60M 133.60M 115.96M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments 0.68M - 0.71M 0.71M 0.63M
Net receivables 70.33M 59.28M 81.43M 81.43M 74.96M
Long term debt 41.97M 41.97M 55.06M - 65.70M
Inventory 15.62M 15.62M 16.83M 16.83M 15.09M
Accounts payable 20.54M 20.54M 26.19M 26.19M 17.97M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -637.92000M - -773.28800M -773.28800M -774.96400M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 19.45M 2.48M 2.07M 2.07M 1.11M
Deferred long term asset charges - - - - -
Non current assets total 454.77M 454.77M 459.46M 459.46M 462.95M
Capital lease obligations 248.41M 248.41M 253.84M - 250.62M
Long term debt total 181.78M - 204.19M - 215.23M
Breakdown 2025-06-30 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Investments - -8.89500M - -7.24700M -
Change to liabilities - - - - -
Total cashflows from investing activities -8.89500M -8.89500M -7.24700M -7.24700M -12.18200M
Net borrowings -13.00000M -13.00000M -11.00000M -11.00000M 66.00M
Total cash from financing activities -178.74200M -178.74200M -146.13900M -146.13900M -137.87600M
Change to operating activities - - - - -
Net income 32.43M 32.43M 23.93M 23.93M 35.90M
Change in cash -4.69400M -4.69400M 6.18M 6.18M -6.41700M
Begin period cash flow 26.14M 26.14M 19.95M 19.95M 26.37M
End period cash flow 21.44M 21.44M 26.14M 26.14M 19.95M
Total cash from operating activities 182.80M 182.80M 159.59M 159.59M 143.68M
Issuance of capital stock - - - - -
Depreciation 136.04M 136.04M 128.43M 128.43M 122.75M
Other cashflows from investing activities 0.10M 0.10M 0.33M 0.33M -5.24800M
Dividends paid 24.95M -24.94600M 19.95M -19.94900M 96.88M
Change to inventory 1.21M 1.21M -1.73400M -1.73400M 5.00M
Change to account receivables 8.32M 8.32M -7.72400M -7.72400M 17.40M
Sale purchase of stock -19.12000M -19.12000M -1.74200M -1.74200M -0.89100M
Other cashflows from financing activities 0.00000M 0.00000M -113.44800M -113.44800M -106.10500M
Change to netincome - - - - -
Capital expenditures 8.41M 8.41M 6.50M 6.50M 6.93M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 9.49M 9.49M 0.49M 0.49M -6.24100M
Stock based compensation 3.44M 3.44M 3.06M 3.06M 1.88M
Other non cash items 1.40M 1.40M 3.68M 3.68M -8.73400M
Free cash flow 174.39M 174.39M 153.09M 153.09M 136.75M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACL
Australian Clinical Labs Ltd		 -0.01 0.47% 2.14 15.64 11.51 0.55 2.80 0.98 3.97
SHL
Sonic Healthcare Ltd		 0.06 0.30% 19.89 17.87 14.58 0.94 1.15 1.46 8.64
IDX
Integral Diagnostics Ltd		 0.02 1.02% 1.99 50.75 13.79 0.99 1.12 1.73 11.06
PEB
Pacific Edge Ltd		 - -% 0.26 - - 22.07 32.65 30.52 -7.8581
MVF
Monash Ivf Group Ltd		 0.002 0.28% 0.71 18.38 13.62 1.06 1.13 1.77 9.34

Reports Covered

Stock Research & News

View All

Profile

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. The company was incorporated in 2020 and is headquartered in Clayton, Australia.

Australian Clinical Labs Ltd

1868-1892 Dandenong Road, Clayton, VIC, Australia, 3168

Key Executives

Name Title Year Born
Ms. Melinda McGrath CEO & Exec. Director NA
Mr. James Davison Chief Financial Officer NA
Mr. Anthony Friedli Chief Operating Officer NA
Mr. Sean Jackson Chief Information Officer NA
Mr. Joe Geran National Marketing Director NA
Associate Prof. Tony Landgren National Medical Director & Chief Pathologist NA
Mr. Chris Brownlow Chief Exec. Officer of New South Wales & Australian Capital Territory NA
Ms. Shae Seymour Chief Exec. Officer of Western Australia NA
Mr. Eric Swayn Chief Exec. Officer of South Australia & Northern Territory NA
Ms. Eleanor Padman B.A., FCIS Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.